Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Oct 8. doi: 10.1038/s41591-018-0197-1. [Epub ahead of print]

PMID:
30297909
2.

Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.

Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R.

Mod Pathol. 2018 Oct 5. doi: 10.1038/s41379-018-0148-x. [Epub ahead of print]

PMID:
30291344
3.

Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility.

Kaur A, Ecker BL, Douglass SM, Kugel CH, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, Weeraratna AT.

Cancer Discov. 2018 Oct 2. pii: CD-18-0193. doi: 10.1158/2159-8290.CD-18-0193. [Epub ahead of print]

PMID:
30279173
4.

Post-Radiation Vascular Lesions of the Breast.

Ronen S, Ivan D, Torres-Cabala CA, Curry JL, Tetzlaff MT, Aung PP, Nagarajan P, Suster S, Prieto VG.

J Cutan Pathol. 2018 Sep 24. doi: 10.1111/cup.13363. [Epub ahead of print] Review.

PMID:
30251277
5.

High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.

Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B, Tetzlaff MT.

Oncoimmunology. 2018 Jul 26;7(9):e1475874. doi: 10.1080/2162402X.2018.1475874. eCollection 2018.

PMID:
30228943
6.

Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.

Lefrançois P, Xie P, Wang L, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Wheeler DA, Duvic M, Litvinov IV.

Oncoimmunology. 2018 May 31;7(8):e1467856. doi: 10.1080/2162402X.2018.1467856. eCollection 2018.

PMID:
30221071
7.

Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs.

Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Oliva ICG, Marchetti D.

Cancer Res. 2018 Sep 15;78(18):5349-5362. doi: 10.1158/0008-5472.CAN-18-0644. Epub 2018 Jul 19.

PMID:
30026332
8.

Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.

Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, Prieto VG, Nelson K, Curry JL.

J Cutan Pathol. 2018 Oct;45(10):786-790. doi: 10.1111/cup.13319. Epub 2018 Aug 3.

PMID:
30021048
9.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

PMID:
29945191
10.

Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.

Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL.

J Cutan Pathol. 2018 Oct;45(10):764-773. doi: 10.1111/cup.13312. Epub 2018 Jul 24.

PMID:
29943453
11.

Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia.

Farah M, Nagarajan P, Curry JL, Tang Z, Kim TB, Aung PP, Torres-Cabala CA, Eterovic AK, Wargo JA, Prieto VG, Tetzlaff MT.

Br J Dermatol. 2018 Jun 13. doi: 10.1111/bjd.16881. [Epub ahead of print]

PMID:
29897634
12.

Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.

Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE.

Am J Dermatopathol. 2018 Nov;40(11):831-835. doi: 10.1097/DAD.0000000000001150.

PMID:
29863571
13.

Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall.

Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):545-549. doi: 10.1111/cup.13263. Epub 2018 May 18.

PMID:
29672900
14.

Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.

Dolkar T, Trinidad CM, Nelson KC, Amaria RN, Nagarajan P, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Curry JL, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):539-544. doi: 10.1111/cup.13262. Epub 2018 May 16.

PMID:
29665030
15.

Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers.

Mauzo SH, Milton DR, Prieto VG, Torres-Cabala CA, Wang WL, Chakravarti N, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Brown RE, Aung PP.

Ann Diagn Pathol. 2018 Jun;34:151-154. doi: 10.1016/j.anndiagpath.2018.03.005. Epub 2018 Mar 15.

PMID:
29660567
16.

Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.

Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):504-507. doi: 10.1111/cup.13150. Epub 2018 Apr 23.

PMID:
29633300
17.

Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma.

Al-Rohil RN, Milton DR, Nagarajan P, Curry JL, Feldmeyer L, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Aung PP.

Hum Pathol. 2018 Jul;77:98-107. doi: 10.1016/j.humpath.2018.03.017. Epub 2018 Mar 28.

PMID:
29601841
18.

Update on Merkel Cell Carcinoma.

Tetzlaff MT, Nagarajan P.

Head Neck Pathol. 2018 Mar;12(1):31-43. doi: 10.1007/s12105-018-0898-2. Epub 2018 Mar 20. Review.

PMID:
29556962
19.

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.

Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL.

J Immunother Cancer. 2018 Feb 12;6(1):14. doi: 10.1186/s40425-018-0323-0.

20.

Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia.

Lewis DJ, Miranda RN, Oh CW, Hinojosa T, Medeiros LJ, Curry JL, Tetzlaff MT, Torres-Cabala CA, Nagarajan P, Ravandi-Kashani F, Duvic M.

Clin Exp Dermatol. 2018 Jun;43(4):449-453. doi: 10.1111/ced.13401. Epub 2018 Feb 9.

PMID:
29423961
21.

A 60-year-old woman with an asymptomatic left lacrimal gland mass found incidentally.

Thakar SD, Sagiv O, Tetzlaff MT, El-Naggar A, Debnam JM, Kandl TJ, Esmaeli B.

Digit J Ophthalmol. 2017 Oct 18;23(4):27-29. doi: 10.5693/djo.03.2017.07.001. eCollection 2017. No abstract available.

22.

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.

Liu S, Tetzlaff MT, Wang T, Chen X, Yang R, Kumar SM, Vultur A, Li P, Martin JS, Herlyn M, Amaravadi R, Li B, Xu X.

Oncotarget. 2017 Dec 5;8(70):115140-115152. doi: 10.18632/oncotarget.22944. eCollection 2017 Dec 29.

23.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
24.

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA.

Oncoimmunology. 2017 Aug 8;6(12):e1361097. doi: 10.1080/2162402X.2017.1361097. eCollection 2017.

25.

Desmoplastic Melanoma of the Periorbital Region.

Thakar S, Kandl T, Sagiv O, Tripathy D, Tetzlaff MT, Kapur S, Myers J, Hwu WJ, Jaber BMY, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr;34(2):e48-e52. doi: 10.1097/IOP.0000000000001015.

PMID:
29194286
26.

Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.

Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG, Curry JL.

Int J Dermatol. 2017 Nov 20. doi: 10.1111/ijd.13833. [Epub ahead of print]

PMID:
29152725
27.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

29.

Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.

Mahajan KR, Ko JS, Tetzlaff MT, Hudgens CW, Billings SD, Cohen JA.

Mult Scler Relat Disord. 2017 Oct;17:12-14. doi: 10.1016/j.msard.2017.06.004. Epub 2017 Jun 22.

PMID:
29055440
30.

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC.

Clin Cancer Res. 2018 Jan 1;24(1):22-32. doi: 10.1158/1078-0432.CCR-17-1807. Epub 2017 Oct 19.

31.

Differential expression of CCR4 in primary cutaneous gamma/delta (γ⁄δ) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy.

Jour G, Aung PP, Merrill ED, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Duvic M, Miranda RN, Torres-Cabala CA.

J Dermatol Sci. 2018 Jan;89(1):88-91. doi: 10.1016/j.jdermsci.2017.08.012. Epub 2017 Sep 1. No abstract available.

PMID:
29030090
32.

TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform.

Lefrançois P, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Duvic M, Litvinov IV.

Front Med (Lausanne). 2017 Sep 22;4:153. doi: 10.3389/fmed.2017.00153. eCollection 2017.

33.

Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M.

JAMA Dermatol. 2017 Dec 1;153(12):1302-1306. doi: 10.1001/jamadermatol.2017.3593.

34.

Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.

Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL.

J Cutan Pathol. 2017 Dec;44(12):1080-1086. doi: 10.1111/cup.13044. Epub 2017 Oct 13.

PMID:
28901560
35.

Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.

Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT.

J Cutan Pathol. 2017 Dec;44(12):1075-1079. doi: 10.1111/cup.13039. Epub 2017 Sep 27.

PMID:
28885734
36.

Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma.

Sagiv O, Thakar SD, Morrell G, Tetzlaff MT, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2018 Jan/Feb;34(1):e24-e27. doi: 10.1097/IOP.0000000000000988.

PMID:
28863117
37.

Coccidioidomycosis Involving Lungs and Skin: A Mimicker of Metastatic Disease.

Saenz-Ibarra B, Prieto VG, Torres-Cabala CA, Huen A, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Aung PP.

Am J Dermatopathol. 2018 Mar;40(3):e41-e43. doi: 10.1097/DAD.0000000000000986.

PMID:
28857979
38.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

39.

Toward a Molecular-Genetic Classification of Spitzoid Neoplasms.

Tetzlaff MT, Reuben A, Billings SD, Prieto VG, Curry JL.

Clin Lab Med. 2017 Sep;37(3):431-448. doi: 10.1016/j.cll.2017.05.003. Review.

PMID:
28802494
40.

Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report.

Lewis DJ, Vin H, Hinojosa T, Tetzlaff MT, Dabaja BS, Duvic M.

J Cutan Med Surg. 2017 Nov/Dec;21(6):568-571. doi: 10.1177/1203475417721425. Epub 2017 Jul 17.

PMID:
28712310
41.

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP.

Oncoimmunology. 2017 May 8;6(6):e1321187. doi: 10.1080/2162402X.2017.1321187. eCollection 2017.

42.

Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.

Litvinov IV, Tetzlaff MT, Thibault P, Gangar P, Moreau L, Watters AK, Netchiporouk E, Pehr K, Prieto VG, Rahme E, Provost N, Gilbert M, Sasseville D, Duvic M.

Oncoimmunology. 2017 Mar 17;6(5):e1306618. doi: 10.1080/2162402X.2017.1306618. eCollection 2017.

43.

Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.

Agarwal A, Gopinath A, Tetzlaff MT, Prieto VG.

Am J Dermatopathol. 2017 Jul;39(7):504-507. doi: 10.1097/DAD.0000000000000690.

PMID:
28609344
44.

Aberrant expression of FLI-1 in melanoma.

Ramani N, Aung PP, Hwu WJ, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Prieto VG, Torres-Cabala CA.

J Cutan Pathol. 2017 Sep;44(9):790-793. doi: 10.1111/cup.12979. Epub 2017 Jul 10.

PMID:
28605142
45.

Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall.

Valero-Torres A, Prieto VG, Nagarajan P, Torres-Cabala CA, Tetzlaff MT, Curry JL, Ivan D, Aung PP.

Am J Dermatopathol. 2017 Jun;39(6):468-470. doi: 10.1097/DAD.0000000000000713.

PMID:
28525424
46.

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaah3560. doi: 10.1126/scitranslmed.aah3560. Erratum in: Sci Transl Med. 2017 Apr 12;9(385):.

47.

Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy.

Shustef E, Torres-Cabala CA, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Aung PP.

Am J Dermatopathol. 2017 Aug;39(8):e116-e118. doi: 10.1097/DAD.0000000000000859.

PMID:
28248716
48.

Isolated Ectopic Cutaneous Atypical Meningioma of the Scalp: Another Mimicker of Primary Adnexal Tumor.

Konopinski J, Prieto VG, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala CA, Fuller GN, Aung PP.

Am J Dermatopathol. 2017 Jul;39(7):545-547. doi: 10.1097/DAD.0000000000000821.

PMID:
28178009
49.

Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.

Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.

Am J Dermatopathol. 2017 Feb;39(2):121-129. doi: 10.1097/DAD.0000000000000688.

PMID:
28134729
50.

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.

Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH.

Mod Pathol. 2017 May;30(5):761-772. doi: 10.1038/modpathol.2016.240. Epub 2017 Jan 27.

Supplemental Content

Loading ...
Support Center